Cullinan Oncology LLC

Yahoo Finance • last month

Cullinan Therapeutics Showcases Compelling Clinical Data in AML for CLN-049, Novel FLT3xCD3 T Cell Engager, in Oral Presentation at the 67th ASH Meeting

CLN-049 monotherapy demonstrates promising efficacy, including multiple complete responses and encouraging response durability, in a heavily pretreated all-comer population of patients with R/R AML 31% CR/CRh rate observed at the highest... Full story

Yahoo Finance • last month

This Biotech Fund Just Dumped $14.8 Million in MBX Biosciences — Right Before Key 2026 Milestones

Key Points Boston-based MPM BioImpact sold 1.3 million shares of MBX Biosciences worth an estimated $14.8 million in the third quarter. The move marked a full exit for MPM BioImpact, which reported holding no shares of MBX at the end of t... Full story

Yahoo Finance • last month

Cullinan Wins FDA Fast Track For CLN-049 In Relapsed/Refractory AML

(RTTNews) - Cullinan Therapeutics, Inc. (CGEM) announced that the U.S. FDA has granted Fast Track Designation to CLN-049, a novel, investigational FLT3xCD3 bispecific T cell engager, for the treatment of R/R acute myeloid leukemia (AML).... Full story

Yahoo Finance • last month

Cullinan Therapeutics Announces Fast Track Designation For CLN-049

(RTTNews) - Cullinan Therapeutics (CGEM) announced that the FDA has granted Fast Track designation to CLN-049 for the treatment of relapsed/refractory acute myeloid leukemia. The company said data from the Phase 1 clinical trial of CLN-049... Full story

Yahoo Finance • last month

Cullinan Therapeutics Receives FDA Fast Track Designation for CLN-049, a Novel FLT3xCD3 T Cell Engager, in Relapsed/Refractory Acute Myeloid Leukemia

Promising efficacy and favorable safety data from the Phase 1 study in heavily pre-treated patients show potential of CLN-049 to address a broad population of AML patients CAMBRIDGE, Mass., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Cullinan The... Full story

Yahoo Finance • 2 months ago

Cullinan Therapeutics to Showcase New Data Demonstrating Compelling Clinical Activity for CLN-049, a Novel FLT3xCD3 T Cell Engager, in AML Patients in an Oral Presentation at the 67th ASH Annual Meeting

CLN-049 demonstrated anti-leukemic activity, including multiple complete responses, in a heavily pretreated population of patients with r/r AML, regardless of FLT3 mutational status ~30% CRc rate observed at clinically active target doses... Full story

Yahoo Finance • 3 months ago

Cullinan Therapeutics Shares Additional Preclinical B Cell Depletion Data for CLN-978, Supporting Clinical Development Across Multiple Autoimmune Diseases, at ACR Convergence 2025

CLN-978 led to rapid and deep B cell depletion in vitro and in vivo in multiple autoimmune diseases CAMBRIDGE, Mass., Oct. 25, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a clinical-stage biopharmaceutical compa... Full story

Yahoo Finance • 4 months ago

Cullinan Therapeutics to Participate in Fireside Chat at the Stifel 2025 Virtual Immunology and Inflammation Forum

CAMBRIDGE, Mass., Sept. 12, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that Jeffrey Jones, M.D.... Full story

Yahoo Finance • 5 months ago

Cullinan Therapeutics to Participate in Upcoming Investor Conferences

CAMBRIDGE, Mass., Aug. 21, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced its participation in the... Full story

Yahoo Finance • 5 months ago

Cullinan Therapeutics GAAP EPS of -$1.07

* Cullinan Therapeutics press release [https://seekingalpha.com/pr/20192720-cullinan-therapeutics-provides-corporate-update-and-reports-second-quarter-2025-financial] (NASDAQ:CGEM [https://seekingalpha.com/symbol/CGEM]): Q2 GAAP EPS of -... Full story

Yahoo Finance • 5 months ago

CULLINAN THERAPEUTICS INC (NASDAQ:CGEM) Reports Wider Q2 2025 Loss, Misses EPS Estimates Amid Rising R&D Costs

CULLINAN THERAPEUTICS INC (NASDAQ:CGEM [https://www.chartmill.com/stock/quote/CGEM]) reported its second-quarter 2025 financial results, posting a net loss of $70.1 million, or $1.07 per share, compared to a net loss of $42.0 million, or $... Full story

Yahoo Finance • 5 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Second Quarter 2025 Financial Results

CLN-978 program now actively enrolling across Phase 1 studies in systemic lupus erythematosus (SLE), rheumatoid arthritis (RA) and Sjögren’s disease BCMA-directed bispecific T cell engager velinotamig in-licensed from Genrix Bio Zipalert... Full story

Yahoo Finance • 6 months ago

InvestingPro's Fair Value model predicted CGEM's significant price correction

Investing.com’s Fair Value analysis has once again demonstrated its effectiveness in identifying mispriced stocks, as evidenced by Cullinan Oncology’s (NASDAQ:CGEM) significant price movement since January 2024. The Fair Value model helps... Full story

Yahoo Finance • 6 months ago

Cullinan Oncology stock rating reiterated at Buy by Clear Street

Investing.com - Clear Street has reiterated its Buy rating and $22.00 price target on Cullinan Oncology Inc. (NASDAQ:CGEM), following the recent approval of a competing drug. The stock, currently trading at $7.76, shows significant upside... Full story

Yahoo Finance • 8 months ago

Cullinan Therapeutics, Taiho Pharmaceutical, and Taiho Oncology to Present Positive Results from Pivotal Phase 2b REZILIENT1 Trial of Zipalertinib at ASCO 2025

CAMBRIDGE, Mass. and TOKYO, Japan and PRINCETON, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), Taiho Pharmaceutical Co., Ltd., and Taiho Oncology, Inc. today announced new positive results from the pi... Full story

Yahoo Finance • 9 months ago

Cullinan Therapeutics to Present Results from REZILIENT1, a Phase 1/2 Trial of Zipalertinib in Patients with Non-Small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutations Who Have Received Prior Therapy, at ASCO 2025

CAMBRIDGE, Mass., April 23, 2025 (GLOBE NEWSWIRE) -- Cullinan Therapeutics, Inc. (Nasdaq: CGEM), a biopharmaceutical company focused on developing modality-agnostic targeted therapies, today announced that results from the REZILIENT1 stu... Full story

Yahoo Finance • 9 months ago

Cullinan Therapeutics Receives Approval from European Medicines Agency to Initiate Phase 1 Trial of CLN-978, a Bispecific CD19 T Cell Engager Administered Subcutaneously, in Patients with Rheumatoid Arthritis

Company-sponsored clinical trial will be initiated at FAU Erlangen-Nuremberg in Germany and Università Cattolica del Sacro Cuore, Rome in Q2 2025 CLN-978 is also being studied in the U.S., Europe, and Australia for systemic lupus erythema... Full story

Yahoo Finance • 11 months ago

Cullinan Therapeutics Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Initial clinical data from global Phase 1 study of CLN-978 in Systemic Lupus Erythematosus (SLE) expected in Q4 2025; CLN-978 remains the first and only development-stage CD19 T cell engager in an autoimmune disease clinical trial in the U... Full story

Yahoo Finance • last year

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market

Amgen's Rocatinlimab Data Beats Placebo In Atopic Dermatitis Trial, But Analyst Says Data Raises Concerns Amid Competitive Market In an investor update on Tuesday, Amgen Inc (NASDAQ:AMGN) released data from Phase 3 trials of rocatinlimab... Full story

Yahoo Finance • 2 years ago

Cullinan Oncology to Present at the 42nd Annual J.P. Morgan Healthcare Conference

Cullinan Oncology, Inc. CAMBRIDGE, Mass., Dec. 18, 2023 (GLOBE NEWSWIRE) --  Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan Oncology”) a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announce... Full story